Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraxpharm Arzneimittel GmbH

https://www.neuraxpharm.de/

Latest From Neuraxpharm Arzneimittel GmbH

Neuraxpharm and Panaxia Partner For Poland, After Germany And France

CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.

 

Europe Poland

Neuraxpharm Recruits Another Viatris Executive To Lead European Expansion

For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.

Executive Changes Strategy

Neuraxpharm Expands Into The Nordics With New Leader From Viatris

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

Europe Executive Changes

Neuraxpharm CEO Confirms Expansion Into New Markets, Including US

In an exclusive interview with Generics Bulletin, Neuraxpharm CEO Jörg-Thomas Dierks reveals that the company plans to expand out of Europe into other markets by acquiring companies in regions such as the US.

Strategy Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
UsernamePublicRestriction

Register